Barrett Katz

Learn More
OBJECTIVE To identify factors associated with a high and low risk of developing multiple sclerosis after an initial episode of optic neuritis. METHODS Three hundred eighty-eight patients who experienced acute optic neuritis between July 1, 1988, and June 30, 1991, were followed up prospectively for the development of multiple sclerosis. Consenting(More)
OBJECTIVE To evaluate the efficacy of a second year of pegaptanib sodium therapy in patients with neovascular age-related macular degeneration (AMD). DESIGN Two concurrent, multicenter, randomized, double-masked, sham-controlled studies (V.I.S.I.O.N. [Vascular Endothelial Growth Factor Inhibition Study in Ocular Neovascularization] trials). PARTICIPANTS(More)
PURPOSE To assess visual function more than 10 years after an episode of optic neuritis in patients enrolled in the Optic Neuritis Treatment Trial. DESIGN Longitudinal follow-up of a randomized clinical trial. METHODS Vision testing included measures of visual acuity, contrast sensitivity, and visual field. Quality of life was assessed with the National(More)
AIMS To evaluate the safety of up to 3 years of pegaptanib sodium therapy in the treatment of neovascular age-related macular degeneration (NV-AMD). METHODS Two concurrent, prospective, multicentre, double-masked studies randomised subjects with all angiographic lesion compositions of NV-AMD to receive intravitreous pegaptanib sodium (0.3, 1 and 3 mg) or(More)
BACKGROUND Participants enrolled in the Optic Neuritis Treatment Trial have been observed for more than a decade to assess the relationship between optic neuritis and the development of clinically definite multiple sclerosis. OBJECTIVE To assess neurologic disability 10 to 12 years after an initial episode of optic neuritis. DESIGN Longitudinal(More)
Alzheimer's disease is a progressive neurologic disorder which may present with visual disturbance before the diagnosis is clearly established. Central acuity and visual field are initially normal. Alzheimer patients may show anomalies of color vision, spatial contrast sensitivity, susceptibility to visual masks, fundus examination, ocular motility, higher(More)
Many neurologic symptoms occur with coughing paroxysms in patients with CF. Few seek medical advice for these symptoms. Rarely, a patient who reports these symptoms should be evaluated further for more serious neurologic conditions, including brain abscess. 12 However, for most patients it seems reasonable to offer reassurance that, although the symptoms(More)
We recorded pattern-reversal electroretinograms, flash electroretinograms, pattern-reversal visual evoked potentials, and flash visual evoked potentials in 6 patients with clinically diagnosed Alzheimer's disease and 6 age- and sex-matched control subjects. The mean amplitude of the pattern-reversal electroretinogram in the Alzheimer patients was(More)
OBJECTIVE To evaluate the safety and efficacy of pegaptanib sodium injection (pegaptanib) in the treatment of diabetic macular edema (DME). DESIGN Randomized, double-masked, multicenter, dose-ranging, controlled trial. PARTICIPANTS Individuals with a best-corrected visual acuity (VA) between 20/50 and 20/320 in the study eye and DME involving the center(More)
Both clinical and preclinical findings have implicated vascular endothelial growth factor (VEGF) in the pathophysiology of diabetic macular edema (DME). VEGF is both a potent enhancer of vascular permeability and a key inducer of angiogenesis. VEGF levels are elevated in the eyes of patients with DME, and in animal models of diabetes this elevation(More)